Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: An update on recent patents

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 1, 2012, Pages 8-18

  Vadlapudi, Aswani D ^a   Vadlapatla, Ramya K ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Antivirals; Cytomegalovirus; Patents; Retinitis; Therapeutics; Treatment

Indexed keywords

1263W 94; 2 AMINOPURINE; 2 BROMO 5,6 DICHLORO 1 BETA DEXTRO RIBOPYRANOSYL 1H BENZIMIDAZOLE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; ADEFOVIR; AIC 246; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CORTICOSTEROID; CYCLOPROPAVIR; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GENE EXPRESSION MODULATOR 132; GW 1263W 94; GW 275175X; IMIDAZOLE DERIVATIVE; METHYLENECYCLOPROPANE DERIVATIVE; OCTADECYLOXYETHYLCIDOFOVIR; PEPTIDE DERIVATIVE; PLACEBO; PROTHYMOSIN ALPHA; SMALL INTERFERING RNA; TOMEGLOVIR; UNCLASSIFIED DRUG; VALCYCLOPROPAVIR; VALGANCICLOVIR; VP 41263;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS RETINITIS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EYE DISEASE; EYE INFECTION; EYE INFLAMMATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAOCULAR HYPOTENSION; KIDNEY DISEASE; LONG TERM CARE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATENT; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPRODUCTIVE TOXICITY; RETINA DETACHMENT; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; SYSTEMIC DISEASE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UVEITIS; VIRUS INHIBITION; VITREOUS HEMORRHAGE;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; HIV; HIV INFECTIONS; HUMANS; PATENTS AS TOPIC;

EID: 84858328093     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112799829765     Document Type: Review

References (79)

1. Heiden D, Ford N, Wilson D, Rodriguez WR, Margolis T, Janssens B, et al. Cytomegalovirus retinitis: The neglected disease of the AIDS pandemic. PLoS Med 2007; 4(12): e334.
2. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71(2-3): 154-63.
3. Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2(3): 112-7.
4. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996; 39(5-6): 401-12.
5. McGavran MH, Smith MG. Ultrastructural, cytochemical, and microchemical observations on cytomegalovirus (salivary gland virus) infection of human cells in tissue culture. Exp Mol Pathol 1965; 76: 1-10.
6. Wright HT, Jr., Goodheart CR, Lielausis A. Human cytomegalovirus. Morphology by negative staining. Virology 1964; 23: 419-24.
7. Rasmussen L. Molecular pathogenesis of human cytomegalovirus infection. Transpl Infect Dis 1999; 1(2): 127-34.
8. Baldick CJ, Jr., Shenk T. Proteins associated with purified human cytomegalovirus particles. J Virol 1996; 70(9): 6097-105.
9. Roby C, Gibson W. Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J Virol 1986; 59(3): 714-27.
10. Gibson W. Protein counterparts of human and simian cytomegaloviruses. Virology 1983; 128(2): 391-406.
11. Gibson W. Structure and assembly of the virion. Intervirology 1996; 39(5-6): 389-400.
12. Spaete RR, Gehrz RC, Landini MP. Human cytomegalovirus structural proteins. J Gen Virol 1994; 75(12): 3287-308.
13. Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 2007; 14(3): 66-71.
14. Gerna G, Baldanti F, Revello MG. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 2004; 65(5): 381-6.
15. Bodaghi B, Slobbe-van Drunen ME, Topilko A, Perret E, Vossen RC, van Dam-Mieras MC, et al. Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis. Invest Ophthalmol Vis Sci 1999; 40(11): 2598-607.
16. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc 1998; 96:111-23; discussion 24-6.
17. Thorne JE, Holbrook JT, Jabs DA, Kempen JH, Nichols C, Meinert CL. Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology 2007; 114(3): 591-8.
18. Deayton JR, Wilson P, Sabin CA, Davey CC, Johnson MA, Emery VC, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14(9): 1163-70.
19. Gariano RF, Rickman LS, Freeman WR. Ocular examination and diagnosis in patients with the acquired immunodeficiency syndrome. West J Med 1993; 158(3): 254-62.
20. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol 2010; 4: 285-99.
21. Holland GN, Buhles WC, Jr., Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 1989; 107(12): 1759-66.
22. Skiest DJ, Chiller T, Chiller K, Park A, Keiser P. Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. Int J STD AIDS 2001; 12(10): 659-64.
23. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology 2007; 114(4): 787-93.
24. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 2006; 113(8): 1441-5.
25. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358(6382): 162-4.
26. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184(12): 1598-602.
27. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65(6): 859-78.
28. Young SH, Morlet N, Heery S, Hollows FC, Coroneo MT. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992; 157(6): 370-3.
29. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH, Jr. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103(1): 17-23.
30. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997; 337(2): 83-90.
31. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004; 11(3): 77-86.
32. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33(5):736-41.
33. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4(11): 928-40.
34. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30(2): 115-33.
35. Kern ER, Rybak RJ, Hartline CB, Bidanset DJ. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antivir Chem Chemother 2001; 12 (Suppl 1): 149-56.
36. Kern ER. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proc 1991; 23(3 Suppl 3): 152-5, discussion 5.
37. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11(3): 383-93.
38. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133(4): 484-98.
39. Wang WW, Ye JJ. Present status and advances in pharmacotherapy for cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. Zhonghua Yan Ke Za Zhi 2010; 46(12): 1148-52.
40. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, 3rd, Davis MG, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole Lriboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46(8): 2365-72.
41. Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS. Inhibition of Epstein-Barr virus replication by a benzimidazole Lriboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol 1999; 73(9): 7271-7.
42. Marschall M, Freitag M, Suchy P, Romaker D, Kupfer R, Hanke M, et al. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 2003; 311(1): 60-71.
43. Krosky PM, Baek MC, Jahng WJ, Barrera I, Harvey RJ, Biron KK, et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003; 77(14): 7720-7.
44. Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 2003; 77(2): 905-14.
45. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002; 46(9): 2969-76.
46. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. Drugs R D 2007; 8(3): 188-92.
47. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Annals Pharmacotherap 2008; 42(10): 1447-57.
48. Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): In vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48(6): 757-67.
49. Weber O, Bender W, Eckenberg P, Goldmann S, Haerter M, Hallenberger S, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res 2001; 49(3): 179-89.
50. McSharry JJ, McDonough A, Olson B, Hallenberger S, Reefschlaeger J, Bender W, et al. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 2001; 45(10): 2925-7.
51. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol 2001; 75(19): 9077-86.
52. Schleiss MR, Bernstein DI, McVoy MA, Stroup G, Bravo F, Creasy B, et al. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res 2005; 65(1): 35-43.
53. Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005; 49(9): 3724-33.
54. Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005; 49(2): 656-62.
55. Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003; 59(3): 163-71.
56. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004; 22(8): 423-7.
57. Quenelle DC, Lampert B, Collins DJ, Rice TL, Painter GR, Kern ER. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010; 202(10): 1492-9.
58. Prichard MN, Kern ER. The search for new therapies for human cytomegalovirus infections. Virus Res 2011; 157(2): 212-21.
59. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 1998; 72(1): 717-25.
60. Kern ER, Hartline CB, Rybak RJ, Drach JC, Townsend LB, Biron KK, et al. Activities of benzimidazole D-and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob Agents Chemother 2004; 48(5): 1749-55.
61. Townsend LB, Devivar RV, Turk SR, Nassiri MR, Drach JC. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J Med Chem 1995; 38(20): 4098-105.
62. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54(3): 1290-7.
63. Mitra, A.K. Acyclovir-peptide analogs. US7825086 (2010).
64. Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/receptor-targeted prodrug design: Strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004; 56(10): 1437-52.
65. Yang C, Tirucherai GS, Mitra AK. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin Biol Ther 2001; 1(2): 159-75.
66. Mitra, A.K., Samanta, S.K., Talluri. R.S. Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment. US7951774 (2011).
67. Kowalik, T.F. RNAi targeting of viruses. US20040248839(2004).
68. Draper, K.G., Kisner, D.L., Anderson, K.P., Chapman, S. Composition and method for treatment of CMV infections. US6153595 (2000).
69. Funaro, A., Gribaudo, G., Landolfo, S. Antibodies against human cytomegalovirus (HCMV). US20110171233 (2011).
70. Nunes, J.J., Milne, J., Bemis, J., Xie, R., Vu, C.B., Ng, P.Y., Disch, J., Salzmann, T., Armistead, D. Sirtuin modulating compounds. US20110130387 (2011).
71. Bemis, J., Disch, J. S, Jirousek, M., Lunsmann, W.J., Ng, P.Y., Vu, C.B. Sirtuin modulating compounds. US7829556 (2010).
72. Tokars, M., Lawrence, R., Bradley, M. PMEA lipid conjugates. US20090111774 (2009).
73. Zimmermann, H., Brueckner, D., Henninger, K., Rosentreter, U., Hendrix, M., Keldenich, J., Lang, D., Radtke, M., Paulsen, D., Kern, A. Heterocyclyamide-substituted imidazoles. US7919489 (2011).
74. Zimmermann, H., Brueckner, D., Heimbach, D., Hendrix, M., Henninger, K., Hewlett, G., Rosentreter, U., Keldenich, J., Lang, D., Radtke, M. Antiviral 4-aminocarbonylamino-substituted imidazole compounds. US7767704 (2010).
75. Fryszman, O.M., Lang, H., Lan, J., Chang, E., Fang, Y. 5-Membered heterocycle-based p38 kinase inhibitors. US20110071152 (2011).
76. Mosoian, A., Klotman, M.E., Teixeira, A. Methods of inhibiting viral infection. US7754687 (2010).
77. Exley, R.W. Treatment of herpes virus related diseases. US20110112117 (2011).
78. Ware, C. Ligand for herpes simplex virus entry mediator and methods of use. US20110171242 (2011).
79. Melnik, L.I., Garry, R.F., Morris, C.A. Peptide compositions and methods for inhibiting herpesvirus infection. WO2011053798 (2011).